Tonix Pharmaceuticals Secures GPO Agreement Covering 35 Million Lives for TONMYA Fibromyalgia Treatment
Tonix Pharmaceuticals announced a group purchasing organization agreement effective May 1, 2026, covering approximately 35 million U.S. commercial lives for its FDA-approved non-opioid fibromyalgia treatment TONMYA, expanding patient access.
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has announced an agreement with a leading group purchasing organization (GPO) that will provide coverage for its FDA-approved fibromyalgia treatment TONMYA to approximately 35 million U.S. commercial lives, representing about 20% of the commercial market. The agreement, effective May 1, 2026, applies standard utilization management criteria and marks a significant step in expanding patient access to the non-opioid therapy.
TONMYA (cyclobenzaprine HCl sublingual tablets) is the first new treatment for fibromyalgia approved in more than 15 years. The company noted that this GPO agreement is part of a broader strategy to secure coverage across commercial and government channels. Tonix already has existing Medicaid coverage in 38 states, covering approximately 55 million lives. The company continues to pursue additional coverage to make TONMYA more widely available to patients suffering from fibromyalgia, a chronic condition characterized by widespread pain, fatigue, and sleep disturbances.
The importance of this announcement lies in the potential to significantly increase patient access to a non-opioid treatment option for fibromyalgia. With the ongoing opioid crisis, having an effective non-addictive alternative is critical. The GPO agreement covers a substantial portion of the commercially insured population, which could drive adoption and revenue growth for Tonix. Additionally, the company’s existing Medicaid coverage in 38 states provides a strong foundation for further market penetration.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Beyond TONMYA, the company’s CNS commercial infrastructure supports its marketed products for acute migraine, including Zembrace SymTouch and Tosymra. Tonix is also exploring the potential of TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder. The company’s pipeline includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, and immunology programs such as TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection.
This GPO agreement is a key milestone for Tonix as it seeks to establish TONMYA as a standard of care in fibromyalgia treatment. By securing coverage for such a large patient population, the company is well-positioned to capture market share and drive revenue. Investors and industry observers will be watching for further updates on coverage expansion and sales performance. For more information, visit the company’s newsroom at https://ibn.fm/TNXP.